[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cancer Immunotherapy-India Market Status and Trend Report 2013-2023

February 2018 | 145 pages | ID: C5E520D75C3EN
MIReports Co., Limited

US$ 2,980.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Report Summary

Cancer Immunotherapy-India Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Cancer Immunotherapy industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole India and Regional Market Size of Cancer Immunotherapy 2013-2017, and development forecast 2018-2023
Main market players of Cancer Immunotherapy in India, with company and product introduction, position in the Cancer Immunotherapy market
Market status and development trend of Cancer Immunotherapy by types and applications
Cost and profit status of Cancer Immunotherapy, and marketing status
Market growth drivers and challenges

The report segments the India Cancer Immunotherapy market as:

India Cancer Immunotherapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North India
Northeast India
East India
South India
West India

India Cancer Immunotherapy Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Melanoma
Colorectal cancer
Prostate cancer
Head and neck cancer
Breast cancer
Lung cancer
Other

India Cancer Immunotherapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals
Clinics
Others

India Cancer Immunotherapy Market: Players Segment Analysis (Company and Product introduction, Cancer Immunotherapy Sales Volume, Revenue, Price and Gross Margin):

Amgen
AstraZeneca
F. Hoffman La-Roche
Bayer AG
Bristol-Myers Squibb
Eli Lilly and Company
Janssen Global Services
Merck
Novartis
Pfizer
Seattle Genetics
Peregrine Pharmaceuticals
Viralytics Ltd
Immunomedics

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

CHAPTER 1 OVERVIEW OF CANCER IMMUNOTHERAPY

1.1 Definition of Cancer Immunotherapy in This Report
1.2 Commercial Types of Cancer Immunotherapy
  1.2.1 Melanoma
  1.2.2 Colorectal cancer
  1.2.3 Prostate cancer
  1.2.4 Head and neck cancer
  1.2.5 Breast cancer
  1.2.6 Lung cancer
  1.2.7 Other
1.3 Downstream Application of Cancer Immunotherapy
  1.3.1 Hospitals
  1.3.2 Clinics
  1.3.3 Others
1.4 Development History of Cancer Immunotherapy
1.5 Market Status and Trend of Cancer Immunotherapy 2013-2023
  1.5.1 India Cancer Immunotherapy Market Status and Trend 2013-2023
  1.5.2 Regional Cancer Immunotherapy Market Status and Trend 2013-2023

CHAPTER 2 INDIA MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of Cancer Immunotherapy in India 2013-2017
2.2 Consumption Market of Cancer Immunotherapy in India by Regions
  2.2.1 Consumption Volume of Cancer Immunotherapy in India by Regions
  2.2.2 Revenue of Cancer Immunotherapy in India by Regions
2.3 Market Analysis of Cancer Immunotherapy in India by Regions
  2.3.1 Market Analysis of Cancer Immunotherapy in North India 2013-2017
  2.3.2 Market Analysis of Cancer Immunotherapy in Northeast India 2013-2017
  2.3.3 Market Analysis of Cancer Immunotherapy in East India 2013-2017
  2.3.4 Market Analysis of Cancer Immunotherapy in South India 2013-2017
  2.3.5 Market Analysis of Cancer Immunotherapy in West India 2013-2017
2.4 Market Development Forecast of Cancer Immunotherapy in India 2017-2023
  2.4.1 Market Development Forecast of Cancer Immunotherapy in India 2017-2023
  2.4.2 Market Development Forecast of Cancer Immunotherapy by Regions 2017-2023

CHAPTER 3 INDIA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole India Market Status by Types
  3.1.1 Consumption Volume of Cancer Immunotherapy in India by Types
  3.1.2 Revenue of Cancer Immunotherapy in India by Types
3.2 India Market Status by Types in Major Countries
  3.2.1 Market Status by Types in North India
  3.2.2 Market Status by Types in Northeast India
  3.2.3 Market Status by Types in East India
  3.2.4 Market Status by Types in South India
  3.2.5 Market Status by Types in West India
3.3 Market Forecast of Cancer Immunotherapy in India by Types

CHAPTER 4 INDIA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Cancer Immunotherapy in India by Downstream Industry
4.2 Demand Volume of Cancer Immunotherapy by Downstream Industry in Major Countries
  4.2.1 Demand Volume of Cancer Immunotherapy by Downstream Industry in North India
  4.2.2 Demand Volume of Cancer Immunotherapy by Downstream Industry in Northeast India
  4.2.3 Demand Volume of Cancer Immunotherapy by Downstream Industry in East India
  4.2.4 Demand Volume of Cancer Immunotherapy by Downstream Industry in South India
  4.2.5 Demand Volume of Cancer Immunotherapy by Downstream Industry in West India
4.3 Market Forecast of Cancer Immunotherapy in India by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CANCER IMMUNOTHERAPY

5.1 India Economy Situation and Trend Overview
5.2 Cancer Immunotherapy Downstream Industry Situation and Trend Overview

CHAPTER 6 CANCER IMMUNOTHERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN INDIA

6.1 Sales Volume of Cancer Immunotherapy in India by Major Players
6.2 Revenue of Cancer Immunotherapy in India by Major Players
6.3 Basic Information of Cancer Immunotherapy by Major Players
  6.3.1 Headquarters Location and Established Time of Cancer Immunotherapy Major Players
  6.3.2 Employees and Revenue Level of Cancer Immunotherapy Major Players
6.4 Market Competition News and Trend
  6.4.1 Merger, Consolidation or Acquisition News
  6.4.2 Investment or Disinvestment News
  6.4.3 New Product Development and Launch

CHAPTER 7 CANCER IMMUNOTHERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Amgen
  7.1.1 Company profile
  7.1.2 Representative Cancer Immunotherapy Product
  7.1.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Amgen
7.2 AstraZeneca
  7.2.1 Company profile
  7.2.2 Representative Cancer Immunotherapy Product
  7.2.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of AstraZeneca
7.3 F. Hoffman La-Roche
  7.3.1 Company profile
  7.3.2 Representative Cancer Immunotherapy Product
  7.3.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of F. Hoffman La-Roche
7.4 Bayer AG
  7.4.1 Company profile
  7.4.2 Representative Cancer Immunotherapy Product
  7.4.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Bayer AG
7.5 Bristol-Myers Squibb
  7.5.1 Company profile
  7.5.2 Representative Cancer Immunotherapy Product
  7.5.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
7.6 Eli Lilly and Company
  7.6.1 Company profile
  7.6.2 Representative Cancer Immunotherapy Product
  7.6.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
7.7 Janssen Global Services
  7.7.1 Company profile
  7.7.2 Representative Cancer Immunotherapy Product
  7.7.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Janssen Global Services
7.8 Merck
  7.8.1 Company profile
  7.8.2 Representative Cancer Immunotherapy Product
  7.8.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Merck
7.9 Novartis
  7.9.1 Company profile
  7.9.2 Representative Cancer Immunotherapy Product
  7.9.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Novartis
7.10 Pfizer
  7.10.1 Company profile
  7.10.2 Representative Cancer Immunotherapy Product
  7.10.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Pfizer
7.11 Seattle Genetics
  7.11.1 Company profile
  7.11.2 Representative Cancer Immunotherapy Product
  7.11.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Seattle Genetics
7.12 Peregrine Pharmaceuticals
  7.12.1 Company profile
  7.12.2 Representative Cancer Immunotherapy Product
  7.12.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Peregrine Pharmaceuticals
7.13 Viralytics Ltd
  7.13.1 Company profile
  7.13.2 Representative Cancer Immunotherapy Product
  7.13.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Viralytics Ltd
7.14 Immunomedics
  7.14.1 Company profile
  7.14.2 Representative Cancer Immunotherapy Product
  7.14.3 Cancer Immunotherapy Sales, Revenue, Price and Gross Margin of Immunomedics

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CANCER IMMUNOTHERAPY

8.1 Industry Chain of Cancer Immunotherapy
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CANCER IMMUNOTHERAPY

9.1 Cost Structure Analysis of Cancer Immunotherapy
9.2 Raw Materials Cost Analysis of Cancer Immunotherapy
9.3 Labor Cost Analysis of Cancer Immunotherapy
9.4 Manufacturing Expenses Analysis of Cancer Immunotherapy

CHAPTER 10 MARKETING STATUS ANALYSIS OF CANCER IMMUNOTHERAPY

10.1 Marketing Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
  10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
  10.2.1 Pricing Strategy
  10.2.2 Brand Strategy
  10.2.3 Target Client
10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach
  12.1.1 Research Programs/Design
  12.1.2 Market Size Estimation
  12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
  12.2.1 Secondary Sources
  12.2.2 Primary Sources
12.3 Reference


More Publications